Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7791985 | 0.97 | RXFP1 (0.39) | P2RY1RXFP1KLKB1MEN1KMT2A | |
| SCHEMBL7791943 | 0.94 | MEN1 (0.42) | ACACBRXFP1KLKB1MEN1KMT2A | |
| SCHEMBL8185021 | 0.89 | MAP3K5 (0.41) | RXFP1KLKB1MEN1KMT2AMAPT | |
| SCHEMBL7801318 | 0.89 | WDR5 (0.41) | ACACBKLKB1MAPTPTGESMAP4K1 | |
| SCHEMBL7792108 | 0.88 | RXFP1 (0.41) | RXFP1KLKB1MAPTPTGESMAP4K1 | |
| Hydrochloric Acid SCHEMBL7801341 | 0.85 | MEN1 (0.43) | RXFP1KLKB1MEN1KMT2AMAPT | |
| SCHEMBL7799939 | 0.84 | MEN1 (0.43) | RXFP1KLKB1MEN1KMT2AMAPT | |
| SCHEMBL8068248 | 0.84 | MEN1 (0.43) | RXFP1KLKB1MEN1KMT2AMAPT | |
| SCHEMBL7799949 | 0.83 | MAP3K5 (0.40) | MEN1KMT2AMAPTKDRMAP4K1 | |
| SCHEMBL7792082 | 0.82 | MEN1 (0.42) | RXFP1MEN1KMT2APTGESKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | SMITHKLINE BEECHAM P.L.C. | 2001-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025045-A1 | Substituted isoquinoline derivatives and their use as anticonvulsants | INA, GRIN2C, GRIN2A | ACACB 1537/4885P2RY1 664/4885RXFP1 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.